- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Inhibitors
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 9004-66-4] Iron dextran
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-107928 |
| Brand: | MCE |
| CAS: | 9004-66-4 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | - |
| Molecular Formula | - |
| SMILES | [Iron dextran] |
Summary
In Vivo
Iron dextran (FeDex, IP, 4 weeks, 300 μL of 10 mg) treatment does not increase NSR iron but causes iron-trapping in the tetinal vasculature
[1]
.
Four weeks of IP FeDex injection in 2-month-old WT mice leads to iron accumulation in the RPE and rVECs, but did not increase NSR iron or induce photoreceptor degeneration
[1]
.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Wild-type (WT) and RS- Hepc KO mice [1] . |
| Dosage: | IP. |
| Administration: | 300 μL of 10 mg daily for 5 days each week for 2 or 4 weeks. |
| Result: | Markedly elevated iron levels in 2 and 4 weeks of FeDex-injection groups, by 365.4-fold and 405.4-fold, respectively, compared with PBS controls. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03279536 | Woman´s Health University Hospital, Egypt |
Iron Deficiency Anemia
|
November 1, 2017 | Phase 1|Phase 2 |
| NCT00704028 | American Regent, Inc. |
Anemia
|
June 2008 | Phase 3 |
| NCT01307007 | American Regent, Inc. |
Iron Deficiency Anemia
|
September 2010 | Phase 2 |
| NCT05714176 | Menoufia University|Tanta University |
CKD - Chronic Kidney Disease
|
February 1, 2023 | Phase 4 |
| NCT02731378 | Shanghai East Hospital |
Chemotherapy-induced Anaemia
|
December 2016 | Phase 4 |
| NCT05340465 | University of Washington|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
Prematurity|Iron-deficiency|Iron Deficiency Anemia|Iron Malabsorption
|
November 27, 2022 | Phase 2 |
| NCT05167734 | Mayo Clinic|National Heart, Lung, and Blood Institute (NHLBI) |
Anemia|Critical Illness
|
November 30, 2021 | Phase 2 |
| NCT01290315 | American Regent, Inc. |
Iron Deficiency Anemia
|
August 2009 | Phase 2 |
| NCT05047211 | The University of Texas Medical Branch, Galveston |
Anemia, Iron Deficiency|Delivery Complication
|
October 7, 2021 | Phase 4 |
| NCT00482716 | St. Bartholomew´s Hospital|National Cancer Institute (NCI) |
Anemia|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Unspecified Adult Solid Tumor, Protocol Specific
|
January 2007 | Phase 3 |
| NCT00401544 | Amgen |
Anemia|Non-Myeloid Malignancies
|
December 2006 | Phase 2 |
| NCT03212781 | Assiut University |
Anemia
|
June 2016 | Phase 3 |
| NCT05960227 | Hospital Civil de Guadalajara |
Anemia, Iron Deficiency|Acute Kidney Injury
|
January 6, 2023 | Phase 2 |
| NCT03438227 | Indiana University |
Iron Deficiency Anemia of Pregnancy|Iron Malabsorption
|
April 15, 2018 | Phase 4 |
| NCT00593619 | London Health Sciences Centre |
Iron Deficiency Anemia|Perioperative Blood Conservation
|
January 2008 | Phase 4 |
| NCT02086838 | Ain Shams University |
Treatment of Iron Deficiency Anemia in Pregnancy
|
July 2013 | Phase 4 |
Appearance
Liquid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Pure form | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
H 2 O : ≥ 50 mg/mL
* "≥" means soluble, but saturation unknown.
References
- [1] Wanting Shu, et al. Iron Accumulates in Retinal Vascular Endothelial Cells But Has Minimal Retinal Penetration After IP Iron Dextran Injection in Mice. Invest Ophthalmol Vis Sci. 2019 Oct 1;60(13):4378-4387.
- [2] D. R. ZIMMERMAN, et al. INJECTABLE IRON-DEXTRAN AND SEVERAL ORAL IRON TREATMENTS FOR THE PREVENTION OF IRONDEFICIENCY ANEMIA OF BABY PIGS x. Journal of Animal Science, Volume 18, Issue 4, November 1959, Pages 1409–1415.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.